赛升药业
(300485)
| 流通市值：20.51亿 | | | 总市值：36.08亿 |
| 流通股本：2.74亿 | | | 总股本：4.82亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 120,164,454.13 | 201,673,605.5 | 217,463,050.57 | 205,198,355.58 |
| 应收票据及应收账款 | 52,415,834.58 | 68,077,891.36 | 67,931,696.98 | 79,460,051.09 |
| 其中：应收票据 | 5,464,775.72 | 6,187,297.74 | 6,677,209.75 | 10,226,885.44 |
| 应收账款 | 46,951,058.86 | 61,890,593.62 | 61,254,487.23 | 69,233,165.65 |
| 预付款项 | 5,345,176.4 | 4,606,105.43 | 4,500,817.9 | 4,664,704.18 |
| 其他应收款合计 | 4,014,921.63 | 4,216,746.76 | 4,165,247.8 | 4,330,269.18 |
| 存货 | 107,062,283.11 | 108,470,021.55 | 99,215,629.59 | 97,456,343.78 |
| 其他流动资产 | 10,648,161.59 | 8,118,871.53 | 8,518,086.14 | 16,860,035.25 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,353,066,844.2 | 1,285,246,631.56 | 1,256,427,218.41 | 1,329,112,625.81 |
| 非流动资产: | | | | |
| 长期股权投资 | 802,905,885.92 | 833,612,729.44 | 892,821,727.83 | 819,539,195.58 |
| 其他非流动金融资产 | 631,810,758.82 | 744,743,715.19 | 786,822,448.31 | 561,967,015.82 |
| 固定资产 | 520,791,025.05 | 530,894,697.42 | 537,862,631.25 | 548,583,230.94 |
| 在建工程 | 1,047,500 | 373,394.5 | 482,239.89 | 557,538.28 |
| 生产性生物资产 | 5,533,333.36 | 5,708,333.35 | 5,810,000 | - |
| 使用权资产 | 12,044,547.55 | 12,132,250.57 | 12,219,953.59 | 12,307,656.61 |
| 无形资产 | 49,951,561.48 | 50,888,747.58 | 51,682,730.35 | 52,723,389.9 |
| 开发支出 | 208,970,118.62 | 202,004,953.08 | 194,513,538.37 | 186,415,058.19 |
| 商誉 | 21,865,087.82 | 21,865,087.82 | 21,865,087.82 | 21,865,087.82 |
| 长期待摊费用 | 0 | - | - | - |
| 递延所得税资产 | 2,424,031.38 | 5,270,797.99 | 5,379,042.81 | 4,567,046.82 |
| 其他非流动资产 | 11,790,983.5 | 11,487,680 | 11,561,280 | 10,994,720 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,269,134,833.5 | 2,418,982,386.94 | 2,521,020,680.22 | 2,219,519,939.96 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,622,201,677.7 | 3,704,229,018.5 | 3,777,447,898.63 | 3,548,632,565.77 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 15,130,989.15 | 10,416,912.84 | 11,420,283.6 | 21,349,933 |
| 应付账款 | 15,130,989.15 | 10,416,912.84 | 11,420,283.6 | 21,349,933 |
| 预收款项 | 352,293.58 | - | - | - |
| 合同负债 | 6,081,914.18 | 6,480,436.57 | 5,587,369.27 | 8,556,717.07 |
| 应付职工薪酬 | 4,755,135.47 | 5,290,703.42 | 5,498,213.24 | 5,756,201.57 |
| 应交税费 | 1,343,060.56 | 1,844,174.8 | 3,071,815.74 | 3,398,240.17 |
| 其他应付款合计 | 22,993,951.16 | 13,529,365.4 | 22,476,740.91 | 15,365,411.05 |
| 一年内到期的非流动负债 | 0 | - | - | - |
| 其他流动负债 | 790,648.84 | 842,456.75 | 726,358.02 | 1,112,373.22 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 51,447,992.94 | 38,404,049.78 | 48,780,780.78 | 55,538,876.08 |
| 非流动负债: | | | | |
| 递延所得税负债 | 103,162,354.73 | 100,869,059.07 | 107,222,485.53 | 81,164,316.41 |
| 其他非流动负债 | 0 | - | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 103,162,354.73 | 100,869,059.07 | 107,222,485.53 | 81,164,316.41 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 154,610,347.67 | 139,273,108.85 | 156,003,266.31 | 136,703,192.49 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 481,666,400 | 481,666,400 | 481,666,400 | 481,666,400 |
| 资本公积 | 845,927,046.31 | 845,927,046.31 | 845,927,046.31 | 845,927,046.31 |
| 其他综合收益 | 917,035.61 | 1,402,872.93 | 1,633,189.09 | -139,155.86 |
| 盈余公积 | 244,683,544.13 | 244,683,544.13 | 244,683,544.13 | 244,683,544.13 |
| 未分配利润 | 1,862,820,659.45 | 1,956,428,662.41 | 2,011,565,792.58 | 1,802,122,263.92 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,436,014,685.5 | 3,530,108,525.78 | 3,585,475,972.11 | 3,374,260,098.5 |
| 少数股东权益 | 31,576,644.53 | 34,847,383.87 | 35,968,660.21 | 37,669,274.78 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,467,591,330.03 | 3,564,955,909.65 | 3,621,444,632.32 | 3,411,929,373.28 |
| 负债和股东权益合计 | 3,622,201,677.7 | 3,704,229,018.5 | 3,777,447,898.63 | 3,548,632,565.77 |
| 公告日期 | 2024-04-10 | 2023-10-27 | 2023-08-25 | 2023-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |